Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Akihito Tsunoda"'
Autor:
Naoki Furuya, Koji Kojima, Hideki Marushima, Kazutaka Kakinuma, Akihito Tsunoda, Eriko Koda, Hajime Tsuruoka, Kohei Nishida, Takeo Inoue, Hisashi Saji, Masamichi Mineshita
Publikováno v:
Thoracic Cancer, Vol 11, Iss 11, Pp 3391-3395 (2020)
Immune checkpoint inhibitors (ICIs) are the key drugs used in patients with non‐small cell lung cancer (NSCLC). However, anti‐PD‐1 therapy might worsen chronic infection by reactivating the immune response to infectious diseases. Here, we descr
Externí odkaz:
https://doaj.org/article/d98249704797403fabf975368c541123
Autor:
Akihito Tsunoda, Kei Morikawa, Takeo Inoue, Teruomi Miyazawa, Masahiro Hoshikawa, Masayuki Takagi, Masamichi Mineshita
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Programmed cell death-1 (PD-1) immune checkpoint inhibitor antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1 (PD-L1). However, there are curre
Externí odkaz:
https://doaj.org/article/cc508a67711147e3b4dd9620ae9e49de
Autor:
Teppei Inoue, Akihito Tsunoda, Eriko Nishimoto, Kohei Nishida, Yuka Komatsubara, Rintaro Onoe, Junko Saji, Masamichi Mineshita
Publikováno v:
Respiratory Medicine Case Reports, Vol 23, Iss , Pp 43-45 (2018)
A 51-year-old male patient was receiving treatment for Mycobacterium abscessus infection for approximately 10 years. However, as his condition gradually progressed to type II respiratory insufficiency, he was referred to our hospital, which was near
Externí odkaz:
https://doaj.org/article/a42013cbd3544e50901f33de8e5e8d25
Autor:
Yusuke Saiki, Masamichi Mineshita, Ayano Usuba, Akihito Tsunoda, Naoki Furuya, Eriko Koda, Hiroki Nishine
Publikováno v:
Internal Medicine
A 44-year-old man presented at our hospital to be evaluated for persistent fever and dyspnea. A chest computed tomography (CT) scan showed diffuse ground glass shadows and a left hilar tumor shadow. Upon further examination, he was found to have leuk
Autor:
Koji Kojima, Hisashi Saji, Hideki Marushima, Takeo Inoue, Eriko Koda, Naoki Furuya, Masamichi Mineshita, Kazutaka Kakinuma, Akihito Tsunoda, Kohei Nishida, Hajime Tsuruoka
Publikováno v:
Thoracic Cancer
Thoracic Cancer, Vol 11, Iss 11, Pp 3391-3395 (2020)
Thoracic Cancer, Vol 11, Iss 11, Pp 3391-3395 (2020)
Immune checkpoint inhibitors (ICIs) are the key drugs used in patients with non‐small cell lung cancer (NSCLC). However, anti‐PD‐1 therapy might worsen chronic infection by reactivating the immune response to infectious diseases. Here, we descr
Autor:
Masamichi Mineshita, Akihito Tsunoda, Kei Morikawa, Baku Oyama, Takeo Inoue, Hirotaka Kida, Tadashi Sakaguchi
Publikováno v:
Internal Medicine
An 83-years-old woman diagnosed with advanced Epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma was administered afatinib as a first-line treatment. On Day 17, the patient presented with grade 3 diarrhea and a blood test analysis sho
Autor:
Junko Saji, Akihito Tsunoda, Kohei Nishida, Teppei Inoue, Yuka Komatsubara, Masamichi Mineshita, Rintaro Onoe, Eriko Nishimoto
Publikováno v:
Respiratory Medicine Case Reports, Vol 23, Iss, Pp 43-45 (2018)
Respiratory Medicine Case Reports
Respiratory Medicine Case Reports
A 51-year-old male patient was receiving treatment for Mycobacterium abscessus infection for approximately 10 years. However, as his condition gradually progressed to type II respiratory insufficiency, he was referred to our hospital, which was near
Autor:
Hiromi Muraoka, Junko Saji, Hiroki Nishine, Takeo Inoue, Teruomi Miyazawa, Yuki Kanno, Mariko Okamoto, Akihito Tsunoda, Eriko Koda, Shinya Azagami, Hiroshi Handa, Masamichi Mineshita
Publikováno v:
Allergy and immunology.
Background: Anti-IgE monoclonal antibody omalizumab, anti-IL-5 antibody mepolizumab and benralizumab have been approved as step 5 treatment. In our previous study, the ratio of bronchial wall thickness to bronchial lumen diameter (T/D), and the perce
Autor:
Teruomi Miyazawa, Masamichi Mineshita, Akihito Tsunoda, Kei Morikawa, Masayuki Takagi, Masahiro Hoshikawa, Takeo Inoue
Publikováno v:
BMC Cancer
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Background Programmed cell death-1 (PD-1) immune checkpoint inhibitor antibody has proven to be effective in advanced non-small cell lung cancer (NSCLC) patients positive for programmed cell death-1 ligand-1 (PD-L1). However, there are currently no p
Autor:
Eriko Koda, Hiroki Nishine, Yusuke Saiki, Akihito Tsunoda, Ayano Usuba, Naoki Furuya, Masamichi Mineshita
Publikováno v:
Internal Medicine; 2021, Vol. 60 Issue 18, p2997-3002, 6p